Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain

Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain

Background: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient. Therefore, we aimed to investigate the disease course in patients with different co...

Full description

Bibliographic Details
Main Authors:	Katarzyna Szewczyk, Aleksandra Wieczorek, Wojciech Młynarski, Szymon Janczar, Mariola Woszczyk, Zuzanna Gamrot, Radosław Chaber, Mariusz Wysocki, Monika Pogorzała, Mirosław Bik-Multanowski, Walentyna Balwierz
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-10-01
Series:	Frontiers in Oncology
Subjects:	2p gain MYCN gain MYCN amplification neuroblastoma structural chromosomal aberrations
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.01018/full

Similar Items

Differences in gene expression and molecular pathway regulation between MYCN amplified and 2p gain neuroblastoma tumors
by: K. Szewczyk
Published: (2020-09-01)

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma
by: Agarwal, P., et al.
Published: (2023)

Enhancer of zeste homolog 2 regulates cell differentiation and proliferation in neuroblastoma
by: Amallia N. Setyawati, et al.
Published: (2014-12-01)

Enhancer of zeste homolog 2 regulates cell differentiation and proliferation in neuroblastoma
by: Amallia N. Setyawati, et al.
Published: (2014-12-01)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
by: Yan Su, et al.
Published: (2020-11-01)

Polymorphisms in MYCN gene and neuroblastoma risk in Chinese children: a 3-center case–control study
by: Zhou H, et al.
Published: (2018-07-01)

A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma
by: Laura D. Gamble, et al.
Published: (2021-04-01)

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma
by: Salvatore Raieli, et al.
Published: (2021-02-01)

Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma
by: Laura Dawn Gamble, et al.
Published: (2012-11-01)

CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma
by: Xin Chen, et al.
Published: (2021-05-01)

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53
by: Joanna S. Yi, et al.
Published: (2021-06-01)

Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene
by: Meehan Maria, et al.
Published: (2012-02-01)

Results of neuroblastoma treatment in Lithuania: a single centre experience
by: Austėja Juškaitė, et al.
Published: (2017-07-01)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
by: Robyn T. Sussman, et al.
Published: (2020-03-01)

Cell Proliferation in Neuroblastoma
by: Laura L. Stafman, et al.
Published: (2016-01-01)

MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2
by: Yi Ding, et al.
Published: (2019-12-01)

Neuroblastomas in Eastern China: a retrospective series study of 275 cases in a regional center
by: Yangyang Ma, et al.
Published: (2018-09-01)

Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples
by: Dinesh Babu Somasundaram, et al.
Published: (2019-01-01)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
by: Peng Zhang, et al.
Published: (2017-11-01)

Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma
by: Xinjie Hu, et al.
Published: (2019-07-01)

Opportunities and challenges of circulating biomarkers in neuroblastoma
by: Ricky M. Trigg, et al.
Published: (2019-05-01)

MycN promotes TRPM7 expression and cell migration in neuroblastoma through a process that involves polyamines
by: Ingo Lange, et al.
Published: (2014-01-01)

Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma
by: Venugopal Gunda, et al.
Published: (2020-09-01)

Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines
by: Yudi Dong, et al.
Published: (2020-02-01)

Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells
by: Mengling Liu, et al.
Published: (2016-10-01)

Drugging the Undruggable: Inhibiting MYCN Signalling
by: Jessica K. Holien, et al.
Published: (2019-10-01)

Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival
by: Simon Keane, et al.
Published: (2020-04-01)

Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
by: S. L. George, et al.
Published: (2020-05-01)

MYCN Function in Neuroblastoma Development
by: Jörg Otte, et al.
Published: (2021-01-01)

Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation
by: Ana Colmenero-Repiso, et al.
Published: (2020-11-01)

Age related gene DST represents an independent prognostic factor for MYCN non-amplified neuroblastoma
by: Haiwei Wang, et al.
Published: (2021-06-01)

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma
by: Abraham, B.J, et al.
Published: (2022)

Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status
by: Monica Currò, et al.
Published: (2020-02-01)

Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice
by: Chao-Cheng Huang, et al.
Published: (2015-10-01)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016-09-01)

PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level
by: Vid Mlakar, et al.
Published: (2019-02-01)

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
by: Zhiheng Li, et al.
Published: (2020-11-01)

Identifizierung und praktische Anwendung molekularer Marker für eine Verbesserung der Prognosebeurteilung humaner Neuroblastome
by: Weber, Axel
Published: (2012)

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma
by: Barbara Marengo, et al.
Published: (2021-02-01)

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells
by: Eleanor M. O’Brien, et al.
Published: (2018-02-01)

Cannot write session to /tmp/vufind_sessions/sess_ts9ebhjofda8mtbed1c878gu6e